nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Alkylating Activity—Mitomycin—urinary bladder cancer	0.507	0.569	CiPCiCtD
Melphalan—Alkylating Activity—Thiotepa—urinary bladder cancer	0.384	0.431	CiPCiCtD
Melphalan—SLC7A5—prostate gland—urinary bladder cancer	0.00217	0.116	CbGeAlD
Melphalan—Chlorambucil—GSTP1—urinary bladder cancer	0.00196	0.657	CrCbGaD
Melphalan—SLC7A5—seminal vesicle—urinary bladder cancer	0.00184	0.0985	CbGeAlD
Melphalan—SLC7A5—epithelium—urinary bladder cancer	0.0016	0.0856	CbGeAlD
Melphalan—SLC7A5—smooth muscle tissue—urinary bladder cancer	0.00154	0.0825	CbGeAlD
Melphalan—SLC7A5—urethra—urinary bladder cancer	0.00146	0.078	CbGeAlD
Melphalan—SLC22A3—prostate gland—urinary bladder cancer	0.00135	0.0723	CbGeAlD
Melphalan—SLC7A5—female reproductive system—urinary bladder cancer	0.00119	0.0636	CbGeAlD
Melphalan—SLC22A3—seminal vesicle—urinary bladder cancer	0.00114	0.0612	CbGeAlD
Melphalan—SLC7A5—vagina—urinary bladder cancer	0.00107	0.0575	CbGeAlD
Melphalan—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.000955	0.0512	CbGeAlD
Melphalan—SLC22A3—renal system—urinary bladder cancer	0.00092	0.0493	CbGeAlD
Melphalan—SLC22A3—urethra—urinary bladder cancer	0.000903	0.0484	CbGeAlD
Melphalan—SLC22A3—female reproductive system—urinary bladder cancer	0.000736	0.0395	CbGeAlD
Melphalan—SLC7A5—lymph node—urinary bladder cancer	0.000694	0.0372	CbGeAlD
Melphalan—SLC22A3—vagina—urinary bladder cancer	0.000666	0.0357	CbGeAlD
Melphalan—Ibuprofen—UGT2B7—urinary bladder cancer	0.000482	0.162	CrCbGaD
Melphalan—SLC22A3—lymph node—urinary bladder cancer	0.000431	0.0231	CbGeAlD
Melphalan—Ibuprofen—CXCL8—urinary bladder cancer	0.000272	0.0915	CrCbGaD
Melphalan—Ibuprofen—PPARG—urinary bladder cancer	0.000188	0.0632	CrCbGaD
Melphalan—Infection—Gemcitabine—urinary bladder cancer	8.46e-05	0.000971	CcSEcCtD
Melphalan—Convulsion—Cisplatin—urinary bladder cancer	8.43e-05	0.000967	CcSEcCtD
Melphalan—Anaphylactic shock—Fluorouracil—urinary bladder cancer	8.37e-05	0.000961	CcSEcCtD
Melphalan—Oedema—Fluorouracil—urinary bladder cancer	8.37e-05	0.000961	CcSEcCtD
Melphalan—Thrombocytopenia—Gemcitabine—urinary bladder cancer	8.34e-05	0.000957	CcSEcCtD
Melphalan—Hyponatraemia—Epirubicin—urinary bladder cancer	8.33e-05	0.000956	CcSEcCtD
Melphalan—Infection—Fluorouracil—urinary bladder cancer	8.32e-05	0.000955	CcSEcCtD
Melphalan—Renal failure acute—Doxorubicin—urinary bladder cancer	8.31e-05	0.000954	CcSEcCtD
Melphalan—Myalgia—Cisplatin—urinary bladder cancer	8.28e-05	0.000951	CcSEcCtD
Melphalan—Skin disorder—Gemcitabine—urinary bladder cancer	8.27e-05	0.00095	CcSEcCtD
Melphalan—Anaemia—Etoposide—urinary bladder cancer	8.23e-05	0.000945	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	8.22e-05	0.000944	CcSEcCtD
Melphalan—Thrombocytopenia—Fluorouracil—urinary bladder cancer	8.2e-05	0.000941	CcSEcCtD
Melphalan—Liver function test abnormal—Methotrexate—urinary bladder cancer	8.18e-05	0.000939	CcSEcCtD
Melphalan—Tachycardia—Fluorouracil—urinary bladder cancer	8.17e-05	0.000938	CcSEcCtD
Melphalan—Anorexia—Gemcitabine—urinary bladder cancer	8.12e-05	0.000932	CcSEcCtD
Melphalan—Urticaria—Thiotepa—urinary bladder cancer	8.04e-05	0.000923	CcSEcCtD
Melphalan—Anorexia—Fluorouracil—urinary bladder cancer	7.98e-05	0.000916	CcSEcCtD
Melphalan—Leukopenia—Etoposide—urinary bladder cancer	7.97e-05	0.000916	CcSEcCtD
Melphalan—Hypotension—Gemcitabine—urinary bladder cancer	7.96e-05	0.000914	CcSEcCtD
Melphalan—Ibuprofen—PTGS2—urinary bladder cancer	7.95e-05	0.0267	CrCbGaD
Melphalan—Anaphylactic shock—Cisplatin—urinary bladder cancer	7.94e-05	0.000911	CcSEcCtD
Melphalan—Oedema—Cisplatin—urinary bladder cancer	7.94e-05	0.000911	CcSEcCtD
Melphalan—Cardiac arrest—Epirubicin—urinary bladder cancer	7.89e-05	0.000905	CcSEcCtD
Melphalan—Infection—Cisplatin—urinary bladder cancer	7.88e-05	0.000905	CcSEcCtD
Melphalan—Hypotension—Fluorouracil—urinary bladder cancer	7.82e-05	0.000898	CcSEcCtD
Melphalan—Cough—Etoposide—urinary bladder cancer	7.77e-05	0.000893	CcSEcCtD
Melphalan—Thrombocytopenia—Cisplatin—urinary bladder cancer	7.77e-05	0.000892	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	7.76e-05	0.000891	CcSEcCtD
Melphalan—Tachycardia—Cisplatin—urinary bladder cancer	7.75e-05	0.000889	CcSEcCtD
Melphalan—Convulsion—Etoposide—urinary bladder cancer	7.72e-05	0.000886	CcSEcCtD
Melphalan—Skin disorder—Cisplatin—urinary bladder cancer	7.71e-05	0.000885	CcSEcCtD
Melphalan—Hyponatraemia—Doxorubicin—urinary bladder cancer	7.7e-05	0.000885	CcSEcCtD
Melphalan—Liver function test abnormal—Epirubicin—urinary bladder cancer	7.66e-05	0.000879	CcSEcCtD
Melphalan—Paraesthesia—Gemcitabine—urinary bladder cancer	7.65e-05	0.000878	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	7.63e-05	0.000876	CcSEcCtD
Melphalan—Dyspnoea—Gemcitabine—urinary bladder cancer	7.59e-05	0.000872	CcSEcCtD
Melphalan—Chest pain—Etoposide—urinary bladder cancer	7.58e-05	0.000871	CcSEcCtD
Melphalan—Anorexia—Cisplatin—urinary bladder cancer	7.57e-05	0.000869	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	7.53e-05	0.000865	CcSEcCtD
Melphalan—Paraesthesia—Fluorouracil—urinary bladder cancer	7.52e-05	0.000863	CcSEcCtD
Melphalan—Dyspnoea—Fluorouracil—urinary bladder cancer	7.46e-05	0.000857	CcSEcCtD
Melphalan—Hypersensitivity—Thiotepa—urinary bladder cancer	7.46e-05	0.000856	CcSEcCtD
Melphalan—Hypotension—Cisplatin—urinary bladder cancer	7.42e-05	0.000852	CcSEcCtD
Melphalan—Decreased appetite—Gemcitabine—urinary bladder cancer	7.4e-05	0.00085	CcSEcCtD
Melphalan—Dyspepsia—Fluorouracil—urinary bladder cancer	7.37e-05	0.000846	CcSEcCtD
Melphalan—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	7.35e-05	0.000844	CcSEcCtD
Melphalan—Fatigue—Gemcitabine—urinary bladder cancer	7.34e-05	0.000843	CcSEcCtD
Melphalan—Cardiac arrest—Doxorubicin—urinary bladder cancer	7.3e-05	0.000838	CcSEcCtD
Melphalan—Pain—Gemcitabine—urinary bladder cancer	7.28e-05	0.000836	CcSEcCtD
Melphalan—Decreased appetite—Fluorouracil—urinary bladder cancer	7.28e-05	0.000836	CcSEcCtD
Melphalan—Pancytopenia—Methotrexate—urinary bladder cancer	7.27e-05	0.000835	CcSEcCtD
Melphalan—Anaphylactic shock—Etoposide—urinary bladder cancer	7.27e-05	0.000835	CcSEcCtD
Melphalan—Asthenia—Thiotepa—urinary bladder cancer	7.26e-05	0.000834	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	7.23e-05	0.00083	CcSEcCtD
Melphalan—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	7.23e-05	0.00083	CcSEcCtD
Melphalan—Infection—Etoposide—urinary bladder cancer	7.22e-05	0.000829	CcSEcCtD
Melphalan—Neutropenia—Methotrexate—urinary bladder cancer	7.16e-05	0.000822	CcSEcCtD
Melphalan—Pruritus—Thiotepa—urinary bladder cancer	7.16e-05	0.000822	CcSEcCtD
Melphalan—Pain—Fluorouracil—urinary bladder cancer	7.16e-05	0.000822	CcSEcCtD
Melphalan—Paraesthesia—Cisplatin—urinary bladder cancer	7.13e-05	0.000818	CcSEcCtD
Melphalan—Thrombocytopenia—Etoposide—urinary bladder cancer	7.12e-05	0.000817	CcSEcCtD
Melphalan—Tachycardia—Etoposide—urinary bladder cancer	7.1e-05	0.000815	CcSEcCtD
Melphalan—Liver function test abnormal—Doxorubicin—urinary bladder cancer	7.08e-05	0.000813	CcSEcCtD
Melphalan—Dyspnoea—Cisplatin—urinary bladder cancer	7.08e-05	0.000812	CcSEcCtD
Melphalan—Skin disorder—Etoposide—urinary bladder cancer	7.06e-05	0.000811	CcSEcCtD
Melphalan—Anorexia—Etoposide—urinary bladder cancer	6.93e-05	0.000796	CcSEcCtD
Melphalan—Diarrhoea—Thiotepa—urinary bladder cancer	6.93e-05	0.000795	CcSEcCtD
Melphalan—Decreased appetite—Cisplatin—urinary bladder cancer	6.9e-05	0.000792	CcSEcCtD
Melphalan—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	6.85e-05	0.000787	CcSEcCtD
Melphalan—Pancytopenia—Epirubicin—urinary bladder cancer	6.81e-05	0.000782	CcSEcCtD
Melphalan—Hypotension—Etoposide—urinary bladder cancer	6.79e-05	0.00078	CcSEcCtD
Melphalan—Pain—Cisplatin—urinary bladder cancer	6.79e-05	0.000779	CcSEcCtD
Melphalan—Neutropenia—Epirubicin—urinary bladder cancer	6.7e-05	0.00077	CcSEcCtD
Melphalan—Stomatitis—Methotrexate—urinary bladder cancer	6.66e-05	0.000764	CcSEcCtD
Melphalan—Urticaria—Fluorouracil—urinary bladder cancer	6.65e-05	0.000764	CcSEcCtD
Melphalan—Paraesthesia—Etoposide—urinary bladder cancer	6.53e-05	0.00075	CcSEcCtD
Melphalan—Dyspnoea—Etoposide—urinary bladder cancer	6.48e-05	0.000744	CcSEcCtD
Melphalan—Hepatobiliary disease—Methotrexate—urinary bladder cancer	6.46e-05	0.000742	CcSEcCtD
Melphalan—Vomiting—Thiotepa—urinary bladder cancer	6.44e-05	0.000739	CcSEcCtD
Melphalan—Rash—Thiotepa—urinary bladder cancer	6.38e-05	0.000733	CcSEcCtD
Melphalan—Dermatitis—Thiotepa—urinary bladder cancer	6.38e-05	0.000732	CcSEcCtD
Melphalan—Decreased appetite—Etoposide—urinary bladder cancer	6.32e-05	0.000726	CcSEcCtD
Melphalan—Pancytopenia—Doxorubicin—urinary bladder cancer	6.3e-05	0.000723	CcSEcCtD
Melphalan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	6.28e-05	0.000721	CcSEcCtD
Melphalan—Fatigue—Etoposide—urinary bladder cancer	6.27e-05	0.00072	CcSEcCtD
Melphalan—Neuropathy peripheral—Epirubicin—urinary bladder cancer	6.26e-05	0.000719	CcSEcCtD
Melphalan—Stomatitis—Epirubicin—urinary bladder cancer	6.23e-05	0.000715	CcSEcCtD
Melphalan—Jaundice—Epirubicin—urinary bladder cancer	6.23e-05	0.000715	CcSEcCtD
Melphalan—Pain—Etoposide—urinary bladder cancer	6.22e-05	0.000714	CcSEcCtD
Melphalan—Neutropenia—Doxorubicin—urinary bladder cancer	6.2e-05	0.000712	CcSEcCtD
Melphalan—Hypersensitivity—Fluorouracil—urinary bladder cancer	6.17e-05	0.000708	CcSEcCtD
Melphalan—Haemoglobin—Methotrexate—urinary bladder cancer	6.16e-05	0.000707	CcSEcCtD
Melphalan—Haemorrhage—Methotrexate—urinary bladder cancer	6.13e-05	0.000704	CcSEcCtD
Melphalan—Hepatitis—Methotrexate—urinary bladder cancer	6.13e-05	0.000704	CcSEcCtD
Melphalan—Asthenia—Gemcitabine—urinary bladder cancer	6.11e-05	0.000701	CcSEcCtD
Melphalan—Urinary tract disorder—Methotrexate—urinary bladder cancer	6.05e-05	0.000695	CcSEcCtD
Melphalan—Hepatobiliary disease—Epirubicin—urinary bladder cancer	6.04e-05	0.000694	CcSEcCtD
Melphalan—Pruritus—Gemcitabine—urinary bladder cancer	6.02e-05	0.000692	CcSEcCtD
Melphalan—Nausea—Thiotepa—urinary bladder cancer	6.01e-05	0.00069	CcSEcCtD
Melphalan—Urethral disorder—Methotrexate—urinary bladder cancer	6.01e-05	0.00069	CcSEcCtD
Melphalan—Pruritus—Fluorouracil—urinary bladder cancer	5.92e-05	0.00068	CcSEcCtD
Melphalan—Hypersensitivity—Cisplatin—urinary bladder cancer	5.85e-05	0.000671	CcSEcCtD
Melphalan—Diarrhoea—Gemcitabine—urinary bladder cancer	5.83e-05	0.000669	CcSEcCtD
Melphalan—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	5.8e-05	0.000666	CcSEcCtD
Melphalan—Urticaria—Etoposide—urinary bladder cancer	5.78e-05	0.000663	CcSEcCtD
Melphalan—Haemoglobin—Epirubicin—urinary bladder cancer	5.77e-05	0.000662	CcSEcCtD
Melphalan—Jaundice—Doxorubicin—urinary bladder cancer	5.76e-05	0.000662	CcSEcCtD
Melphalan—Stomatitis—Doxorubicin—urinary bladder cancer	5.76e-05	0.000662	CcSEcCtD
Melphalan—Haemorrhage—Epirubicin—urinary bladder cancer	5.74e-05	0.000659	CcSEcCtD
Melphalan—Hepatitis—Epirubicin—urinary bladder cancer	5.74e-05	0.000659	CcSEcCtD
Melphalan—Diarrhoea—Fluorouracil—urinary bladder cancer	5.73e-05	0.000658	CcSEcCtD
Melphalan—Asthenia—Cisplatin—urinary bladder cancer	5.69e-05	0.000654	CcSEcCtD
Melphalan—Urinary tract disorder—Epirubicin—urinary bladder cancer	5.67e-05	0.000651	CcSEcCtD
Melphalan—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.64e-05	0.000647	CcSEcCtD
Melphalan—Urethral disorder—Epirubicin—urinary bladder cancer	5.62e-05	0.000646	CcSEcCtD
Melphalan—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.59e-05	0.000642	CcSEcCtD
Melphalan—Immune system disorder—Methotrexate—urinary bladder cancer	5.54e-05	0.000636	CcSEcCtD
Melphalan—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.52e-05	0.000634	CcSEcCtD
Melphalan—Diarrhoea—Cisplatin—urinary bladder cancer	5.43e-05	0.000624	CcSEcCtD
Melphalan—Alopecia—Methotrexate—urinary bladder cancer	5.42e-05	0.000622	CcSEcCtD
Melphalan—Vomiting—Gemcitabine—urinary bladder cancer	5.41e-05	0.000622	CcSEcCtD
Melphalan—Rash—Gemcitabine—urinary bladder cancer	5.37e-05	0.000616	CcSEcCtD
Melphalan—Dermatitis—Gemcitabine—urinary bladder cancer	5.36e-05	0.000616	CcSEcCtD
Melphalan—Hypersensitivity—Etoposide—urinary bladder cancer	5.36e-05	0.000615	CcSEcCtD
Melphalan—Haemoglobin—Doxorubicin—urinary bladder cancer	5.34e-05	0.000613	CcSEcCtD
Melphalan—Flushing—Epirubicin—urinary bladder cancer	5.32e-05	0.000611	CcSEcCtD
Melphalan—Vomiting—Fluorouracil—urinary bladder cancer	5.32e-05	0.000611	CcSEcCtD
Melphalan—Haemorrhage—Doxorubicin—urinary bladder cancer	5.31e-05	0.000609	CcSEcCtD
Melphalan—Hepatitis—Doxorubicin—urinary bladder cancer	5.31e-05	0.000609	CcSEcCtD
Melphalan—Rash—Fluorouracil—urinary bladder cancer	5.28e-05	0.000606	CcSEcCtD
Melphalan—Dermatitis—Fluorouracil—urinary bladder cancer	5.27e-05	0.000606	CcSEcCtD
Melphalan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	5.24e-05	0.000602	CcSEcCtD
Melphalan—Asthenia—Etoposide—urinary bladder cancer	5.22e-05	0.000599	CcSEcCtD
Melphalan—Connective tissue disorder—Doxorubicin—urinary bladder cancer	5.22e-05	0.000599	CcSEcCtD
Melphalan—Urethral disorder—Doxorubicin—urinary bladder cancer	5.2e-05	0.000597	CcSEcCtD
Melphalan—Immune system disorder—Epirubicin—urinary bladder cancer	5.18e-05	0.000595	CcSEcCtD
Melphalan—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.17e-05	0.000594	CcSEcCtD
Melphalan—Pruritus—Etoposide—urinary bladder cancer	5.14e-05	0.000591	CcSEcCtD
Melphalan—Arrhythmia—Epirubicin—urinary bladder cancer	5.12e-05	0.000588	CcSEcCtD
Melphalan—Alopecia—Epirubicin—urinary bladder cancer	5.07e-05	0.000582	CcSEcCtD
Melphalan—Nausea—Gemcitabine—urinary bladder cancer	5.06e-05	0.000581	CcSEcCtD
Melphalan—Vomiting—Cisplatin—urinary bladder cancer	5.05e-05	0.000579	CcSEcCtD
Melphalan—Rash—Cisplatin—urinary bladder cancer	5e-05	0.000575	CcSEcCtD
Melphalan—Dermatitis—Cisplatin—urinary bladder cancer	5e-05	0.000574	CcSEcCtD
Melphalan—Diarrhoea—Etoposide—urinary bladder cancer	4.97e-05	0.000571	CcSEcCtD
Melphalan—Nausea—Fluorouracil—urinary bladder cancer	4.97e-05	0.000571	CcSEcCtD
Melphalan—Anaemia—Methotrexate—urinary bladder cancer	4.93e-05	0.000566	CcSEcCtD
Melphalan—Flushing—Doxorubicin—urinary bladder cancer	4.93e-05	0.000566	CcSEcCtD
Melphalan—Immune system disorder—Doxorubicin—urinary bladder cancer	4.79e-05	0.000551	CcSEcCtD
Melphalan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.78e-05	0.000549	CcSEcCtD
Melphalan—Leukopenia—Methotrexate—urinary bladder cancer	4.78e-05	0.000548	CcSEcCtD
Melphalan—Arrhythmia—Doxorubicin—urinary bladder cancer	4.74e-05	0.000544	CcSEcCtD
Melphalan—Nausea—Cisplatin—urinary bladder cancer	4.71e-05	0.000541	CcSEcCtD
Melphalan—Alopecia—Doxorubicin—urinary bladder cancer	4.69e-05	0.000539	CcSEcCtD
Melphalan—Cough—Methotrexate—urinary bladder cancer	4.66e-05	0.000535	CcSEcCtD
Melphalan—Convulsion—Methotrexate—urinary bladder cancer	4.62e-05	0.000531	CcSEcCtD
Melphalan—Vomiting—Etoposide—urinary bladder cancer	4.62e-05	0.000531	CcSEcCtD
Melphalan—Anaemia—Epirubicin—urinary bladder cancer	4.62e-05	0.00053	CcSEcCtD
Melphalan—Rash—Etoposide—urinary bladder cancer	4.58e-05	0.000526	CcSEcCtD
Melphalan—Dermatitis—Etoposide—urinary bladder cancer	4.58e-05	0.000526	CcSEcCtD
Melphalan—Myalgia—Methotrexate—urinary bladder cancer	4.54e-05	0.000522	CcSEcCtD
Melphalan—Chest pain—Methotrexate—urinary bladder cancer	4.54e-05	0.000522	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.51e-05	0.000518	CcSEcCtD
Melphalan—Leukopenia—Epirubicin—urinary bladder cancer	4.47e-05	0.000513	CcSEcCtD
Melphalan—Cough—Epirubicin—urinary bladder cancer	4.36e-05	0.0005	CcSEcCtD
Melphalan—Anaphylactic shock—Methotrexate—urinary bladder cancer	4.36e-05	0.0005	CcSEcCtD
Melphalan—Convulsion—Epirubicin—urinary bladder cancer	4.33e-05	0.000497	CcSEcCtD
Melphalan—Infection—Methotrexate—urinary bladder cancer	4.33e-05	0.000497	CcSEcCtD
Melphalan—Nausea—Etoposide—urinary bladder cancer	4.32e-05	0.000496	CcSEcCtD
Melphalan—Anaemia—Doxorubicin—urinary bladder cancer	4.27e-05	0.00049	CcSEcCtD
Melphalan—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.26e-05	0.00049	CcSEcCtD
Melphalan—Chest pain—Epirubicin—urinary bladder cancer	4.25e-05	0.000488	CcSEcCtD
Melphalan—Myalgia—Epirubicin—urinary bladder cancer	4.25e-05	0.000488	CcSEcCtD
Melphalan—Skin disorder—Methotrexate—urinary bladder cancer	4.23e-05	0.000486	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.22e-05	0.000485	CcSEcCtD
Melphalan—Anorexia—Methotrexate—urinary bladder cancer	4.15e-05	0.000477	CcSEcCtD
Melphalan—Leukopenia—Doxorubicin—urinary bladder cancer	4.14e-05	0.000475	CcSEcCtD
Melphalan—Anaphylactic shock—Epirubicin—urinary bladder cancer	4.08e-05	0.000468	CcSEcCtD
Melphalan—Oedema—Epirubicin—urinary bladder cancer	4.08e-05	0.000468	CcSEcCtD
Melphalan—Hypotension—Methotrexate—urinary bladder cancer	4.07e-05	0.000467	CcSEcCtD
Melphalan—Infection—Epirubicin—urinary bladder cancer	4.05e-05	0.000465	CcSEcCtD
Melphalan—Cough—Doxorubicin—urinary bladder cancer	4.03e-05	0.000463	CcSEcCtD
Melphalan—Convulsion—Doxorubicin—urinary bladder cancer	4e-05	0.00046	CcSEcCtD
Melphalan—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.99e-05	0.000458	CcSEcCtD
Melphalan—Tachycardia—Epirubicin—urinary bladder cancer	3.98e-05	0.000457	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.97e-05	0.000456	CcSEcCtD
Melphalan—Skin disorder—Epirubicin—urinary bladder cancer	3.96e-05	0.000455	CcSEcCtD
Melphalan—Myalgia—Doxorubicin—urinary bladder cancer	3.93e-05	0.000452	CcSEcCtD
Melphalan—Chest pain—Doxorubicin—urinary bladder cancer	3.93e-05	0.000452	CcSEcCtD
Melphalan—Paraesthesia—Methotrexate—urinary bladder cancer	3.91e-05	0.000449	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.91e-05	0.000449	CcSEcCtD
Melphalan—Anorexia—Epirubicin—urinary bladder cancer	3.89e-05	0.000446	CcSEcCtD
Melphalan—Dyspnoea—Methotrexate—urinary bladder cancer	3.88e-05	0.000446	CcSEcCtD
Melphalan—Dyspepsia—Methotrexate—urinary bladder cancer	3.83e-05	0.00044	CcSEcCtD
Melphalan—Hypotension—Epirubicin—urinary bladder cancer	3.81e-05	0.000437	CcSEcCtD
Melphalan—Decreased appetite—Methotrexate—urinary bladder cancer	3.79e-05	0.000435	CcSEcCtD
Melphalan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.77e-05	0.000433	CcSEcCtD
Melphalan—Oedema—Doxorubicin—urinary bladder cancer	3.77e-05	0.000433	CcSEcCtD
Melphalan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.76e-05	0.000432	CcSEcCtD
Melphalan—Fatigue—Methotrexate—urinary bladder cancer	3.75e-05	0.000431	CcSEcCtD
Melphalan—Infection—Doxorubicin—urinary bladder cancer	3.75e-05	0.00043	CcSEcCtD
Melphalan—Pain—Methotrexate—urinary bladder cancer	3.72e-05	0.000428	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.71e-05	0.000426	CcSEcCtD
Melphalan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.69e-05	0.000424	CcSEcCtD
Melphalan—Tachycardia—Doxorubicin—urinary bladder cancer	3.68e-05	0.000423	CcSEcCtD
Melphalan—Skin disorder—Doxorubicin—urinary bladder cancer	3.66e-05	0.000421	CcSEcCtD
Melphalan—Paraesthesia—Epirubicin—urinary bladder cancer	3.66e-05	0.00042	CcSEcCtD
Melphalan—Dyspnoea—Epirubicin—urinary bladder cancer	3.63e-05	0.000417	CcSEcCtD
Melphalan—Anorexia—Doxorubicin—urinary bladder cancer	3.59e-05	0.000413	CcSEcCtD
Melphalan—Dyspepsia—Epirubicin—urinary bladder cancer	3.59e-05	0.000412	CcSEcCtD
Melphalan—Decreased appetite—Epirubicin—urinary bladder cancer	3.54e-05	0.000407	CcSEcCtD
Melphalan—Hypotension—Doxorubicin—urinary bladder cancer	3.52e-05	0.000405	CcSEcCtD
Melphalan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.52e-05	0.000404	CcSEcCtD
Melphalan—Fatigue—Epirubicin—urinary bladder cancer	3.51e-05	0.000403	CcSEcCtD
Melphalan—Pain—Epirubicin—urinary bladder cancer	3.49e-05	0.0004	CcSEcCtD
Melphalan—Urticaria—Methotrexate—urinary bladder cancer	3.46e-05	0.000397	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.44e-05	0.000395	CcSEcCtD
Melphalan—Paraesthesia—Doxorubicin—urinary bladder cancer	3.39e-05	0.000389	CcSEcCtD
Melphalan—Dyspnoea—Doxorubicin—urinary bladder cancer	3.36e-05	0.000386	CcSEcCtD
Melphalan—Dyspepsia—Doxorubicin—urinary bladder cancer	3.32e-05	0.000381	CcSEcCtD
Melphalan—Decreased appetite—Doxorubicin—urinary bladder cancer	3.28e-05	0.000376	CcSEcCtD
Melphalan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.26e-05	0.000374	CcSEcCtD
Melphalan—Fatigue—Doxorubicin—urinary bladder cancer	3.25e-05	0.000373	CcSEcCtD
Melphalan—Urticaria—Epirubicin—urinary bladder cancer	3.24e-05	0.000372	CcSEcCtD
Melphalan—Pain—Doxorubicin—urinary bladder cancer	3.22e-05	0.00037	CcSEcCtD
Melphalan—Hypersensitivity—Methotrexate—urinary bladder cancer	3.21e-05	0.000368	CcSEcCtD
Melphalan—Asthenia—Methotrexate—urinary bladder cancer	3.12e-05	0.000359	CcSEcCtD
Melphalan—Pruritus—Methotrexate—urinary bladder cancer	3.08e-05	0.000354	CcSEcCtD
Melphalan—Hypersensitivity—Epirubicin—urinary bladder cancer	3e-05	0.000345	CcSEcCtD
Melphalan—Urticaria—Doxorubicin—urinary bladder cancer	3e-05	0.000344	CcSEcCtD
Melphalan—Diarrhoea—Methotrexate—urinary bladder cancer	2.98e-05	0.000342	CcSEcCtD
Melphalan—Asthenia—Epirubicin—urinary bladder cancer	2.92e-05	0.000336	CcSEcCtD
Melphalan—Pruritus—Epirubicin—urinary bladder cancer	2.88e-05	0.000331	CcSEcCtD
Melphalan—Diarrhoea—Epirubicin—urinary bladder cancer	2.79e-05	0.00032	CcSEcCtD
Melphalan—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.78e-05	0.000319	CcSEcCtD
Melphalan—Vomiting—Methotrexate—urinary bladder cancer	2.77e-05	0.000318	CcSEcCtD
Melphalan—Rash—Methotrexate—urinary bladder cancer	2.75e-05	0.000315	CcSEcCtD
Melphalan—Dermatitis—Methotrexate—urinary bladder cancer	2.74e-05	0.000315	CcSEcCtD
Melphalan—Asthenia—Doxorubicin—urinary bladder cancer	2.71e-05	0.000311	CcSEcCtD
Melphalan—Pruritus—Doxorubicin—urinary bladder cancer	2.67e-05	0.000306	CcSEcCtD
Melphalan—Vomiting—Epirubicin—urinary bladder cancer	2.59e-05	0.000298	CcSEcCtD
Melphalan—Nausea—Methotrexate—urinary bladder cancer	2.59e-05	0.000297	CcSEcCtD
Melphalan—Diarrhoea—Doxorubicin—urinary bladder cancer	2.58e-05	0.000296	CcSEcCtD
Melphalan—Rash—Epirubicin—urinary bladder cancer	2.57e-05	0.000295	CcSEcCtD
Melphalan—Dermatitis—Epirubicin—urinary bladder cancer	2.57e-05	0.000295	CcSEcCtD
Melphalan—Nausea—Epirubicin—urinary bladder cancer	2.42e-05	0.000278	CcSEcCtD
Melphalan—Vomiting—Doxorubicin—urinary bladder cancer	2.4e-05	0.000275	CcSEcCtD
Melphalan—Rash—Doxorubicin—urinary bladder cancer	2.38e-05	0.000273	CcSEcCtD
Melphalan—Dermatitis—Doxorubicin—urinary bladder cancer	2.38e-05	0.000273	CcSEcCtD
Melphalan—Nausea—Doxorubicin—urinary bladder cancer	2.24e-05	0.000257	CcSEcCtD
